ArticleInternational journal of molecular sciences2022

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells.

Sara Verdura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.